Silo Pharma, Inc.

Clinical/early-stage biotech — micro clinical-stage, deep losses, cash-rich.

Strengths

• Liquidity — current ratio 11.4 (82nd)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Net lossNet loss (net margin -5863.5%)
• Buying back stockNet buyback — share count -51%/yr over 4y